GlassScriptPhysician profile
William R Harris
NPI 1447281928
$2,551.61
in general payments reported to CMS, 2019-2025
24 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $117 · 2021: $53.84 · 2022: $113 · 2023: $119 · 2024: $209 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,100.11 | 2019-2020 | |
| Lilly USA, LLC | $278.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $269.56 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $156.61 | 2019-2025 | Eterna |
| Treace Medical Concepts, INC. | $113.44 | 2022 | |
| Glaxosmithkline, LLC. | $88.74 | 2019-2023 | Shingrix, Arexvy |
| Alkermes, INC. | $83.00 | 2023-2025 | Aristada, Lybalvi |
| Amgen INC. | $70.05 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $62.96 | 2023-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $53.84 | 2021 | |
| Stryker Corporation | $49.36 | 2025 | Flowtriever |
| Antares Pharma, INC. | $34.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.23 | 2020 | |
| Esperion Therapeutics, INC. | $22.32 | 2023 | Nexletol |
| Atricure, INC. | $21.00 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.35 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $14.98 | 2020 | |
| Merck Sharp & Dohme LLC | $14.98 | 2019 | |
| Eisai INC. | $14.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.94 | 2019 | |
| Astellas Pharma US INC | $12.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.